Dr. Landon Chan
陳瓏
Specific Research / Sites of Interest
- Hepato-pancreatico-biliary cancer- Stereotactic body radiotherapy
- Combination of radiotherapy and immunotherapy
- Neuroendocrine Tumour
Short Biography
Dr. Landon Chan is a clinical oncologist by training. He joined the Department of Clinical Oncology at the Chinese University of Hong Kong as an Assistant Professor (clinical) in 2023. Prior to his career in medicine, he was trained as a Mathematician and received his Bachelor of Arts from Carleton College in Minnesota, United States. After working at the Mayo Clinic for one year as a statistical analysis programmer, he returned to Hong Kong to pursue his career in clinical medicine. He obtained his medical degree from the Chinese University of Hong Kong in 2017 and became a fellow of the Royal College of Radiologists in 2022. He also received a MSc degree in Precision Cancer Medicine from Oxford University in 2022.Dr. Landon Chan has a long history of interest in personalized medicine. Fully convinced of the potentials of using sequencing technology to understand tumour biology and hence tailor-made personalized treatment, he has participated in multiple bioinformatics projects in renowned international research groups, including Prof. Dennis Lo’s and Prof. Kevin Yip’s group at the Chinese University of Hong Kong, Prof. Mark Gerstein’s group at the Yale University, and Prof. Francesca Buffa and Dr. Simon Lord’s group at the Oxford University, with hands-on experience on DNA-seq and RNA-seq data.
His current research interest includes clinical and translational studies on hepatopancreatico-biliary and neuroendocrine cancers, and how to combine radiotherapy and immunotherapy as part of a personalized therapeutic treatment strategy.
Most Representative Publications
1. Chan SL, Ryoo BY, Mo F, Chan LL, Cheon JK, Li L, Wong KH, Yim N, Kim HY, Yoo CH. Multicentre Phase II Trial of Cabozantinib in Patients with Hepatocellular Carcinoma after Immune Checkpoint Inhibitor Treatment. Journal of Hepatology. 2024. |
2. Chan LL, Mok K, Chan SL. Radiotherapy following Intrahepatic Progression on Immunotherapy in Advanced Hepatocellular Carcinoma. Journal of Hepatology. 2024. |
3. Chan LL, Chan SL. Drug development for hepatocellular carcinoma. The Lancet Oncology. 2023. |
4. Chan LL*, Kung JWC*, Chan SL. Neoadjuvant Immunotherapy for Early-stage Hepatocellular Carcinoma: The Arts and Science. ESMO Gastrointestinal Oncology. 2023. *Contribute equally |
5. Chan LL, Lam KY, Lam D, Lau YM, Li L, Ng KKC, Tang RSY, Chan SL. Risk and impact of thromboembolism in patients with pancreatic carcinoma. Hong Kong Journal of Medicine. 2023. |
6. Chan LL, Chan SL. The Evolving Role of Lenvatinib at the New Era of First-Line HCC Treatment. Clinical and Molecular Hepatology. 2023. |
7. Chan LL, Chan SL. Novel Perspectives in Immune Checkpoints Inhibitors and the Management of Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma. Cancers (Basel). 2022. |
8. Sethi A, Gu M, Gumusgoz E, Chan LL, Yan KK, Rozowsky J, Barozzi I, Afzal V, Akiyama JA, Plajzer-Frick I, Yan C, Novak CS, Kato M, Garvin TH, Pham Q, Harrington A, Mannion BJ, Lee EA, Fukuda-Yuzawa Y, Visel A, Dickel DE, Yip KY, Sutton R, Pennacchio LA, Gerstein M. Supervised enhancer prediction with epigenetic pattern recognition and targeted validation. Nature Methods. 2020. |
9. Chan LL, Chan SL. Systemic treatment of pancreatic neuroendocrine tumors. Surgical Practice. 2019. |
10. Chan LL, Jiang PY. Bioinformatics analysis of circulating cell-free DNA sequencing data. Clinical Biochemistry. 2015. |